Related Experiment Video

Updated: Aug 29, 2026

Inducible and Reversible Dominant-negative (DN) Protein Inhibition
08:35

Inducible and Reversible Dominant-negative (DN) Protein Inhibition

Published on: January 7, 2019

Full-length dominant-negative survivin for cancer immunotherapy

Vladimir Pisarev1, Bin Yu, Raoul Salup

  • 1University of Nebraska Medical Center Eppley Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|December 26, 2003
PubMed
Abstract

Insights

Dendritic cells (DCs) engineered with dominant-negative survivin generate strong survivin-specific T-cell responses against cancer cells. This approach shows promise for cancer immunotherapy with minimal impact on healthy hematopoietic progenitor cells.

Area of Science:

  • Immunology
  • Cancer Research
  • Cell Biology

Background:

  • Survivin is a key protein in cancer cell survival and proliferation.
  • Dominant-negative survivin can inhibit survivin's function.
  • Dendritic cells (DCs) are crucial for initiating immune responses.

Purpose of the Study:

  • To evaluate the efficacy of DCs modified with dominant-negative survivin for cancer immunotherapy.
  • To assess the T-cell response against survivin-derived peptides after DC transduction.
  • To determine if this immunotherapy impacts hematopoietic progenitor cells (HPCs).

Main Methods:

  • Mononuclear cells were isolated from healthy donors and prostate cancer patients.
  • DCs were transduced using an adenoviral vector carrying the dominant-negative survivin gene.
  • T-cell responses were measured using IFN-gamma ELISpot and CTL assays against survivin peptides and tumor cells.

Main Results:

  • Significant T-cell responses were observed in most participants against survivin-derived epitopes.
  • Cytotoxic T-lymphocyte (CTL) activity was effective against survivin-expressing tumor cells (MCF-7).
  • Antisurvivin CTLs did not significantly impair the colony-forming ability of normal CD34(+) HPCs.

Conclusions:

  • DCs transduced with dominant-negative survivin can induce potent, tumor-specific CTL responses.
  • This immunotherapy approach demonstrates selectivity, sparing normal hematopoietic progenitor cells.
  • The findings support the potential clinical application of this DC-based cancer vaccine strategy.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...